85 related articles for article (PubMed ID: 27060053)
1. The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.
Jamnagerwalla J; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
J Urol; 2016 Sep; 196(3):715-20. PubMed ID: 27060053
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial.
Moore CM; Robertson NL; Jichi F; Damola A; Ambler G; Giganti F; Ridout AJ; Bott SR; Winkler M; Ahmed HU; Arya M; Mitra AV; McCartan N; Freeman A; Jameson C; Castro R; Gambarota G; Whitcher BJ; Allen C; Kirkham A; Emberton M
J Urol; 2017 Apr; 197(4):1006-1013. PubMed ID: 27871928
[TBL] [Abstract][Full Text] [Related]
3. Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis.
Chavez AH; Scott Coffield K; Hasan Rajab M; Jo C
Asian J Androl; 2013 Mar; 15(2):246-8. PubMed ID: 23353723
[TBL] [Abstract][Full Text] [Related]
4. Psychotherapy and phosphodiesterase-5 inhibitor in early rehabilitation after radical prostatectomy: a prospective randomised controlled trial.
Naccarato AM; Reis LO; Ferreira U; Denardi F
Andrologia; 2016 Dec; 48(10):1183-1187. PubMed ID: 27062069
[TBL] [Abstract][Full Text] [Related]
5. Sexuality in men after prostate cancer surgery: a qualitative interview study.
Schantz Laursen B
Scand J Caring Sci; 2017 Mar; 31(1):120-127. PubMed ID: 27074959
[TBL] [Abstract][Full Text] [Related]
6. Results of tadalafil treatment in patients following an open nerve-sparing radical prostatectomy.
Hirik E; Bozkurt A; Karabakan M; Onuk Ö; Balcı MB; Aydın M; Çakan M; Nuhoglu B
Arch Ital Urol Androl; 2016 Mar; 88(1):4-6. PubMed ID: 27072168
[TBL] [Abstract][Full Text] [Related]
7. Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome.
Berney DM; Beltran L; Fisher G; North BV; Greenberg D; Møller H; Soosay G; Scardino P; Cuzick J
Br J Cancer; 2016 May; 114(10):1078-83. PubMed ID: 27100731
[TBL] [Abstract][Full Text] [Related]
8. Immediate versus delayed prostatectomy: Nationwide population-based study (.).
Loeb S; Folkvaljon Y; Robinson D; Makarov DV; Bratt O; Garmo H; Stattin P
Scand J Urol; 2016 Aug; 50(4):246-54. PubMed ID: 27067998
[TBL] [Abstract][Full Text] [Related]
9. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
10. Metabolic syndrome in prostate cancer: impact on risk and outcomes.
Karzai FH; Madan RA; Dahut WL
Future Oncol; 2016 Aug; 12(16):1947-55. PubMed ID: 27067408
[TBL] [Abstract][Full Text] [Related]
11. Understanding and Managing Erectile Dysfunction in Patients Treated for Cancer.
Voznesensky M; Annam K; Kreder KJ
J Oncol Pract; 2016 Apr; 12(4):297-304. PubMed ID: 27072383
[TBL] [Abstract][Full Text] [Related]
12. Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Urology; 2016 Jul; 93():68-76. PubMed ID: 27079130
[TBL] [Abstract][Full Text] [Related]
13. Threat of Sexual Disqualification: The Consequences of Erectile Dysfunction and Other Sexual Changes for Gay and Bisexual Men With Prostate Cancer.
Ussher JM; Perz J; Rose D; Dowsett GW; Chambers S; Williams S; Davis I; Latini D
Arch Sex Behav; 2017 Oct; 46(7):2043-2057. PubMed ID: 27102603
[TBL] [Abstract][Full Text] [Related]
14. Safety and Potential Effect of a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-Label Phase I Clinical Trial.
Haahr MK; Jensen CH; Toyserkani NM; Andersen DC; Damkier P; Sørensen JA; Lund L; Sheikh SP
EBioMedicine; 2016 Mar; 5():204-10. PubMed ID: 27077129
[TBL] [Abstract][Full Text] [Related]
15. [Testosterone therapy].
Diemer T; Hauptmann A; Wagenlehner FM
Urologe A; 2016 Apr; 55(4):539-48; quiz 549-50. PubMed ID: 27067659
[TBL] [Abstract][Full Text] [Related]
16. Prostate Biopsy is Associated with an Increased Risk of Erectile Dysfunction.
Whitson JM; Murray KS; Thrasher JB
J Urol; 2016 Jul; 196(1):21-3. PubMed ID: 27067375
[No Abstract] [Full Text] [Related]
17. Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?
Gupta RT; Brown AF; Silverman RK; Tay KJ; Madden JF; George DJ; Polascik TJ
AJR Am J Roentgenol; 2016 Jul; 207(1):87-95. PubMed ID: 27064383
[TBL] [Abstract][Full Text] [Related]
18. Circulating Folate and Vitamin B
Price AJ; Travis RC; Appleby PN; Albanes D; Barricarte Gurrea A; Bjørge T; Bueno-de-Mesquita HB; Chen C; Donovan J; Gislefoss R; Goodman G; Gunter M; Hamdy FC; Johansson M; King IB; Kühn T; Männistö S; Martin RM; Meyer K; Neal DE; Neuhouser ML; Nygård O; Stattin P; Tell GS; Trichopoulou A; Tumino R; Ueland PM; Ulvik A; de Vogel S; Vollset SE; Weinstein SJ; Key TJ; Allen NE;
Eur Urol; 2016 Dec; 70(6):941-951. PubMed ID: 27061263
[TBL] [Abstract][Full Text] [Related]
19. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
Chen H; Liu X; Brendler CB; Ankerst DP; Leach RJ; Goodman PJ; Lucia MS; Tangen CM; Wang L; Hsu FC; Sun J; Kader AK; Isaacs WB; Helfand BT; Zheng SL; Thompson IM; Platz EA; Xu J
Prostate; 2016 Sep; 76(12):1120-9. PubMed ID: 27197965
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
